October 28, 2020

Our second session provides an overview of the regulatory environment and what we're seeing from an international markets perspective.

Mounting evidence of safety and efficacy is improving the social perception of psychedelics, helping us drop and walk away from social baggage. The potential health benefits of psychedelics present significant business opportunities within the mental health sector, which is attracting a growing number of entrepreneurs, investors and operators.

LSD, psilocybin, MDMA, mescaline, DMT and many other psychedelics are listed in the 1971 Convention on Psychotropic Substances and as a result are scheduled as controlled substances in most jurisdictions. Although this legal classification creates specific barriers to entry, operators with the right skillsets see significant business opportunities within this space. If you have an interest in this market, you won't want to miss the opportunity to join the Canadian Securities Exchange (the CSE), MNP LLP and Borden Ladner Gervais LLP (BLG), featuring Zuber Lawler and Del Duca, Stifel Financial Corporation, Red Light Holland and Sansero Life Sciences Inc. for a webinar series that will address the business opportunities and risks associated with this sector.

The series brings together leaders and experts in the psychedelics sector who will share their knowledge and expertise on trends, opportunities and challenges in Canada and around the world.

Watch the 2nd webinar of the series below

In case you missed session 1, view the recorded webinar here. Session 1 explored the business trends and legal implications as well as what you need to know from a capital markets perspective.

By: David Wood

Services: Capital Markets